Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.6% Following Insider Selling

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 0.6% during trading on Friday after an insider sold shares in the company. The stock traded as low as $6.10 and last traded at $6.13. Approximately 767,167 shares changed hands during trading, a decline of 87% from the average daily volume of 5,942,486 shares. The stock had previously closed at $6.17.

Specifically, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares in the company, valued at approximately $4,606,442.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.27, for a total value of $71,772.69. Following the transaction, the director now directly owns 7,121,322 shares of the company’s stock, valued at approximately $44,650,688.94. The disclosure for this sale can be found here. In other news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at $3,939,803.28. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RXRX. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC decreased their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday. KeyCorp lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Jefferies Financial Group reduced their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Price Performance

The business has a 50-day moving average of $7.33 and a 200 day moving average of $8.82. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.38) EPS. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of RXRX. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals in the 1st quarter worth $26,000. National Bank of Canada FI raised its stake in shares of Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after buying an additional 1,500 shares during the period. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after buying an additional 6,036 shares in the last quarter. Amalgamated Bank grew its stake in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the period. Finally, Oxford Wealth Group LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth approximately $106,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.